​

Atara Biotherapeutics (ATRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ATRA Stock Forecast

Atara Biotherapeutics (ATRA) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $18.00 and a low of $10.00. This represents a 73.05% increase from the last price of $8.09.

- $4 $8 $12 $16 $20 High: $18 Avg: $14 Low: $10 Last Closed Price: $8.09

ATRA Stock Rating

Atara Biotherapeutics stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (50.00%), 0 Hold (0.00%), 1 Sell (50.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 1 0 1 Strong Sell Sell Hold Buy Strong Buy

ATRA Forecast vs Benchmarks

TypeNameUpside
StockAtara Biotherapeutics73.05%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$10.00$14.00
Last Closing Price$8.09$8.09$8.09
Upside/Downside-23.61%73.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-42--6
Dec, 24-43-18
Nov, 24333-110
Oct, 243431112
Sep, 243431112
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Benjamin BurnettStifel Nicolaus$10.00$7.5831.93%23.61%
Aug 16, 2024Salim SyedMizuho Securities$18.00$6.83163.54%122.50%
Aug 09, 2022Goldman Sachs$3.00$3.87-22.48%-62.92%
May 24, 2022Goldman Sachs$4.00$4.85-17.53%-50.56%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 20, 2024Rodman & RenshawBuyinitialise
Aug 09, 2022Goldman SachsSellSellhold
May 24, 2022Goldman SachsSellSellhold

Financial Forecast

EPS Forecast

$-150 $-110 $-70 $-30 $10 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.15$-3.63$-2.24$-2.61-----
Avg Forecast$-97.19$-83.35$-50.03$-61.13$-9.50$-6.78$-6.34$-7.98$-5.86
High Forecast$-130.45$-111.87$-69.65$-61.35$-15.99$-9.09$-15.02$-17.39$-5.86
Low Forecast$-61.81$-53.01$-35.93$-60.90$-2.03$-5.26$-0.84$1.42$-5.86
Surprise %-95.73%-95.64%-95.52%-95.73%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$20.34M$63.57M$8.57M-----
Avg Forecast$15.00M$41.63M$96.77M$6.77M$111.80M$79.75M$87.35M$148.29M$199.25M
High Forecast$10.80M$29.97M$75.78M$6.14M$98.70M$79.75M$87.35M$148.29M$199.25M
Low Forecast$18.95M$52.58M$125.94M$7.38M$124.91M$79.75M$87.35M$148.29M$199.25M
Surprise %--51.14%-34.30%26.65%-----

Net Income Forecast

$-6B $-5B $-3B $-2B $-800M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-306.62M$-340.14M$-228.30M$-276.13M-----
Avg Forecast$-4.12B$-307.71M$-233.47M$-276.13M$-38.18M$-30.40M$-33.59M$-33.83M$-24.83M
High Forecast$-5.53B$-369.25M$-294.75M$-347.82M$-67.76M$-38.51M$-63.64M$-73.66M$-24.83M
Low Forecast$-2.62B$-246.16M$-172.19M$-204.44M$-8.60M$-22.29M$-3.55M$6.01M$-24.83M
Surprise %-92.55%10.54%-2.21%------

ATRA Forecast FAQ

Is Atara Biotherapeutics stock a buy?

Atara Biotherapeutics stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Atara Biotherapeutics is a favorable investment for most analysts.

What is Atara Biotherapeutics's price target?

Atara Biotherapeutics's price target, set by 2 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $10 at the low end to $18 at the high end, suggesting a potential 73.05% change from the previous close price of $8.09.

How does Atara Biotherapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Atara Biotherapeutics stock forecast shows a 73.05% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Atara Biotherapeutics over the past three months?

  • January 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.
  • November 2024: 30.00% Strong Buy, 30.00% Buy, 30.00% Hold, 0% Sell, 10.00% Strong Sell.

What is Atara Biotherapeutics’s EPS forecast?

Atara Biotherapeutics's average annual EPS forecast for its fiscal year ending in December is -9.5 for 2024, a 263.98% increase from the reported $-2.61 in 2023. The prediction for 2025 is $-6.78, $-6.34 for 2026, $-7.98 for 2027, and $-5.86 for 2028.

What is Atara Biotherapeutics’s revenue forecast?

Atara Biotherapeutics's average annual revenue forecast for its fiscal year ending in December is $111.8M for 2024, a 1204.13% increase from the reported $8.57M in 2023. The forecast for 2025 is $79.75M, $87.35M for 2026, $148.29M for 2027, and $199.25M for 2028.

What is Atara Biotherapeutics’s net income forecast?

For its fiscal year ending in December, Atara Biotherapeutics's average annual net income forecast is $-38.176M for 2024, reflecting a -86.17% decrease from the reported $-276M in 2023. The projection for 2025 is $-30.402M, $-33.595M for 2026, $-33.826M for 2027, and $-24.832M for 2028.